Garuda’s mission is to bring curative blood stem cell therapy to patients worldwide suffering from serious diseases, while eliminating the dependency on donor or patient cells for transplants. Garuda’s lead program, GRDA-21, is an off-the-shelf, self-renewing blood stem cell therapy enabling rapid and broad access to consistent, durable, HLA-compatible, and transgene-free therapy. GRDA-21 has the potential to replace bone marrow transplant in 120+ diseases, offering enhanced efficacy, safety, and accessibility. GRDA-21 will enter the clinic in 2024 in two patient populations: transfusion-dependent thalassemia and a basket study in bone marrow failure syndromes. Clinical proof of concept would be available by the end of 2024. Beyond this, Garuda intends to develop GRDA-21 in other rare diseases and in severe autoimmune disorders. Garuda is also developing separate programs as potentially curative treatments for HIV/AIDS, and leukemias, lymphomas and other malignancies.